Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

Essential for the website to function (navigation, security, session). They cannot be disabled.

Improve usability: remembering language, region and your preferences.

Help us understand how the site is used (page views, audience) to optimise it.

Allow relevant advertising to be shown and campaigns to be measured.